HISTORY

Building a Better Tomorrow, Every Day

Every day we are innovating and evolving into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.

2020

ACQUISITION

Acquired Portola Pharmaceuticals, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders

ACQUISITION

Acquired Achillion Pharmaceuticals, the company that began development of two oral factor D inhibitors

2019

APPROVAL

Treatment approved for adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)

ABOUT aHUS

APPROVAL

First complement inhibitor approved for adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)

ABOUT NMOSD
Chelsey, living with NMOSD, sitting on a couch

CHELSEY
LIVING WITH NMOSD

PARTNERSHIP

Established partnerships with Caelum Biosciences, Zealand Pharma, and Affibody

2018

APPROVAL

Treatment approved for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

ABOUT PNH
Victor, diagnosed with PNH at 27 years old

VICTOR
LIVING WITH PNH

PARTNERSHIP

Established partnerships with Complement Pharma and Dicerna

PIPELINE

ACQUISITION

Acquired Syntimmune, the company that began development of a treatment for rare IgG-mediated diseases

ACQUISITION

Acquired Wilson Therapeutics, the company that began development of a treatment for Wilson Disease

COMPANY MILESTONE

Opened global headquarters in Boston

Alexion's global headquarters opening ceremony in Boston

2017

PARTNERSHIP

Partnered with Halozyme Therapeutics and established license agreement for ENHANZE® drug-delivery technology

PIPELINE

APPROVAL

First complement inhibitor approved for adult patients with generalized Myasthenia Gravis (gMG)

ABOUT gMG
Jesse, diagnosed with gMG

JESSE
LIVING WITH gMG

2016

COMPANY MILESTONE

Opened the Center of Excellence in New Haven

2015

APPROVAL

First treatment approved for patients with lysosomal acid lipase deficiency (LAL-D)

ABOUT LAL-D

APPROVAL

First treatment approved for patients with hypophosphatasia (HPP)

ABOUT HPP
Evie, diagnosed with HPP at 2 weeks old, playing on a playground

EVIE
LIVING WITH HPP

ACQUISITION

Acquired sebelipase alfa, a potential treatment for patients living with LAL-D

2012

ACQUISITION

Acquired asfostase alfa, a potential treatment for patients living with HPP

2011

APPROVAL

First treatment approved for patients with atypical hemolytic uremic syndrome (aHUS)

ABOUT aHUS

2007

APPROVAL

First treatment approved for patients with paroxysmal nocturnal hemoglobinuria (PNH)

ABOUT PNH
Joe, diagnosed with PNH at 24 years old, training for mixed martial arts

JOE
LIVING WITH PNH

1996

COMPANY MILESTONE

Alexion goes public with ticker ALXN

1992

COMPANY MILESTONE

Alexion founded in New Haven, CT

Alexion's original location in New Haven, CT

Related Topics

Stay on top of what we do every day

NEWS & MEDIA

Jill, diagnosed with aHUS at 28 years old, with her daughter
Help is out there and we’re not alone anymore.”
JILL LIVING WITH aHUS